CN104997808A - 用于治疗癌症的方法和组合物 - Google Patents

用于治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN104997808A
CN104997808A CN201510355863.5A CN201510355863A CN104997808A CN 104997808 A CN104997808 A CN 104997808A CN 201510355863 A CN201510355863 A CN 201510355863A CN 104997808 A CN104997808 A CN 104997808A
Authority
CN
China
Prior art keywords
cisplatin
cancer
present
treatment
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510355863.5A
Other languages
English (en)
Chinese (zh)
Inventor
安杰丽卡·伯格
汉斯·亨德里克斯
伯纳德斯·瑞德马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX USA Inc
Original Assignee
KOMINOX USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMINOX USA Inc filed Critical KOMINOX USA Inc
Publication of CN104997808A publication Critical patent/CN104997808A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201510355863.5A 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物 Pending CN104997808A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US61/039,987 2008-03-27
US12/408,864 2009-03-23
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
CN2009801187686A CN102046187A (zh) 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801187686A Division CN102046187A (zh) 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物

Publications (1)

Publication Number Publication Date
CN104997808A true CN104997808A (zh) 2015-10-28

Family

ID=41114644

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510355863.5A Pending CN104997808A (zh) 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物
CN2009801187686A Pending CN102046187A (zh) 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801187686A Pending CN102046187A (zh) 2008-03-27 2009-03-24 用于治疗癌症的方法和组合物

Country Status (20)

Country Link
US (2) US20090246291A1 (https=)
EP (1) EP2268292B1 (https=)
JP (2) JP5543956B2 (https=)
KR (1) KR101634138B1 (https=)
CN (2) CN104997808A (https=)
AU (1) AU2009228378B2 (https=)
BR (1) BRPI0909164A2 (https=)
CA (1) CA2719766C (https=)
CY (1) CY1120536T1 (https=)
DK (1) DK2268292T3 (https=)
ES (1) ES2656762T3 (https=)
HU (1) HUE036609T2 (https=)
LT (1) LT2268292T (https=)
MX (1) MX2010010621A (https=)
PL (1) PL2268292T3 (https=)
PT (1) PT2268292T (https=)
RU (1) RU2508116C2 (https=)
SI (1) SI2268292T1 (https=)
WO (1) WO2009120697A2 (https=)
ZA (1) ZA201006988B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
ES2718637T3 (es) * 2010-08-24 2019-07-03 Gtx Inc Compuestos para el tratamiento del cáncer
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
CN103826645A (zh) * 2011-05-12 2014-05-28 得克萨斯系统大学评议会 砷在癌症治疗保护中的用途
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
AU2019239671B2 (en) 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
HUE036609T2 (hu) 2018-07-30
AU2009228378A1 (en) 2009-10-01
JP5543956B2 (ja) 2014-07-09
WO2009120697A3 (en) 2010-02-18
US20090246291A1 (en) 2009-10-01
MX2010010621A (es) 2011-04-05
ES2656762T3 (es) 2018-02-28
WO2009120697A2 (en) 2009-10-01
EP2268292A2 (en) 2011-01-05
CY1120536T1 (el) 2019-07-10
CA2719766C (en) 2017-10-31
SI2268292T1 (en) 2018-03-30
CA2719766A1 (en) 2009-10-01
KR20110009664A (ko) 2011-01-28
EP2268292A4 (en) 2011-05-11
PL2268292T3 (pl) 2018-06-29
LT2268292T (lt) 2018-03-26
KR101634138B1 (ko) 2016-06-28
AU2009228378B2 (en) 2014-07-17
US20180055812A1 (en) 2018-03-01
RU2010143893A (ru) 2012-05-10
RU2508116C2 (ru) 2014-02-27
WO2009120697A4 (en) 2010-04-15
CN102046187A (zh) 2011-05-04
PT2268292T (pt) 2018-02-19
DK2268292T3 (en) 2018-03-12
JP2011515481A (ja) 2011-05-19
ZA201006988B (en) 2012-05-30
JP2014101387A (ja) 2014-06-05
EP2268292B1 (en) 2017-12-27
BRPI0909164A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
CN104997808A (zh) 用于治疗癌症的方法和组合物
Rudin et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
US20200281921A1 (en) Cancer treatment with combination of plinabulin and taxane
EP2127652A1 (en) Method for treating cancer using anticancer agent in combination
KR102418766B1 (ko) 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
Vorobiof et al. First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
Kollmannsberger et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
JP2014144979A (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
JP2021063014A (ja) 白血病治療薬
McCain Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options
JP2005511663A5 (https=)
JP2005511663A (ja) 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用
Kang et al. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
EP1740170A2 (en) Combination therapy with azd2171 and platinum anti-tumour agent
CN112168960A (zh) 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK1152250B (en) Method and compositions for treatment of cancer
HK1152250A (en) Method and compositions for treatment of cancer
NZ786609A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151028

RJ01 Rejection of invention patent application after publication